Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Adler

Showing results (71-80 of 202) with videos related to

Pageof 21
Sort By:
The Lancet. Oncology|March 31, 2015
NICE guidance on pomalidomide for relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomibMartyn J Burke, Elisabeth George, Amanda I Adler
The Lancet. Oncology|October 2, 2012
NICE guidance on abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimenMatthew Dyer, Fiona Rinaldi, Elisabeth George, et al.
Journal of Oral Surgery (American Dental Association : 1965)|July 1, 1973
Metastatic bronchogenic carcinoma to the maxilla: report of caseC I Adler, G C Sotereanos, J G Valdivieso
The Lancet. Oncology|May 29, 2016
Cabazitaxel for metastatic hormone-relapsed prostate cancer treated with docetaxelRosemary Lovett, Victoria Kelly, Melinda Goodall, et al.
The Lancet. Diabetes & Endocrinology|March 13, 2021
NICE guidance on dapagliflozin for chronic heart failure with reduced ejection fractionAmanda I Adler, Emma Douch, Lorna Dunning, et al.
The Lancet. Oncology|May 20, 2019
NICE guidance on nivolumab with ipilimumab for untreated advanced renal cell carcinomaAmanda I Adler, Adam Brooke, Ahmed Elsada, et al.
Refu'At Ha-Peh Veha-Shinayim (Tel Aviv, Israel : 1969)|October 1, 1978
Expanded duties of auxiliaries: a survey of opinions of dental and non-dental groups in IsraelM Sela, J Z Anaise, Y Sharav, et al.
The Lancet. Haematology|December 28, 2020
NICE guidance on caplacizumab for treating acute acquired thrombotic thrombocytopenia purpuraMary Hughes, Carl Prescott, Nicole Elliott, et al.
Current Opinion in Nephrology and Hypertension|April 12, 2005
What is the evidence that microalbuminuria is a predictor of cardiovascular disease events?Matthew F Yuyun, Amanda I Adler, Nicholas J Wareham
The Lancet. Diabetes & Endocrinology|September 7, 2019
NICE guidance on dapagliflozin with insulin for type 1 diabetesAmanda I Adler, Sharlene Ting, Ross Dent, et al.
Pageof 21

Showing results (71-80 of 202) with videos related to

Sort By:
Pageof 21
The Lancet. Oncology|March 31, 2015
NICE guidance on pomalidomide for relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomibMartyn J Burke, Elisabeth George, Amanda I Adler
The Lancet. Oncology|October 2, 2012
NICE guidance on abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimenMatthew Dyer, Fiona Rinaldi, Elisabeth George, et al.
Journal of Oral Surgery (American Dental Association : 1965)|July 1, 1973
Metastatic bronchogenic carcinoma to the maxilla: report of caseC I Adler, G C Sotereanos, J G Valdivieso
The Lancet. Oncology|May 29, 2016
Cabazitaxel for metastatic hormone-relapsed prostate cancer treated with docetaxelRosemary Lovett, Victoria Kelly, Melinda Goodall, et al.
The Lancet. Diabetes & Endocrinology|March 13, 2021
NICE guidance on dapagliflozin for chronic heart failure with reduced ejection fractionAmanda I Adler, Emma Douch, Lorna Dunning, et al.
The Lancet. Oncology|May 20, 2019
NICE guidance on nivolumab with ipilimumab for untreated advanced renal cell carcinomaAmanda I Adler, Adam Brooke, Ahmed Elsada, et al.
Refu'At Ha-Peh Veha-Shinayim (Tel Aviv, Israel : 1969)|October 1, 1978
Expanded duties of auxiliaries: a survey of opinions of dental and non-dental groups in IsraelM Sela, J Z Anaise, Y Sharav, et al.
The Lancet. Haematology|December 28, 2020
NICE guidance on caplacizumab for treating acute acquired thrombotic thrombocytopenia purpuraMary Hughes, Carl Prescott, Nicole Elliott, et al.
Current Opinion in Nephrology and Hypertension|April 12, 2005
What is the evidence that microalbuminuria is a predictor of cardiovascular disease events?Matthew F Yuyun, Amanda I Adler, Nicholas J Wareham
The Lancet. Diabetes & Endocrinology|September 7, 2019
NICE guidance on dapagliflozin with insulin for type 1 diabetesAmanda I Adler, Sharlene Ting, Ross Dent, et al.
Pageof 21